B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common pediatric cancer. Although pediatric ALL is cured in over 90% of cases, children with high-risk BCP-ALL present increased chance of treatment failure and relapse.
Renal ischemia-reperfusion injury (IRI) is a type of acute kidney injury commonly affecting hospitalized patients and associated with poor outcomes, including increased risk of death in severe cases. IRI is caused by a transient reduction in renal blood flow followed by blood reperfusion.
Alveus Therapeutics Inc. has obtained IND clearance from the FDA for ALV-100, for chronic weight management, enabling initiation of a phase Ib study. Dosing has now commenced in the study.
The immune system is a critical factor of host survival, allowing resistance to infections and maintaining tissue integrity. The activation of immune responses requires precise regulation to assure a balance between the benefits and costs of these responses. Moreover, the theory of antagonistic pleiotropy proposes that traits beneficial to early-life fitness may sustain costs that manifest later in life, after the period of strongest natural selection, where aging introduces further complexities for cooperative defenses. As a result of this, hosts of different ages may manifest distinct disease courses despite infection with the same pathogen.
Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, glaucoma, inflammatory bowel disease, multiple sclerosis, neurodegeneration, psoriasis and rheumatoid arthritis, among others.
Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.
Acerand Therapeutics (Hong Kong) Ltd. has divulged new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.